Ratings for OptimizeRx (NASDAQ:OPRX) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $8.25, along with a high estimate of $16.00 and a low estimate of $5.00. A 44.26% drop is evident in the current average compared to the previous average price target of $14.80.

Deciphering Analyst Ratings: An In-Depth Analysis

In examining recent analyst actions, we gain insights into how financial experts perceive OptimizeRx. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of OptimizeRx's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.

Stay up to date on OptimizeRx analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind OptimizeRx

OptimizeRx's Financial Performance

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Over the 3 months period, OptimizeRx showcased positive performance, achieving a revenue growth rate of 30.48% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.

Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching -42.82%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): OptimizeRx's ROE stands out, surpassing industry averages. With an impressive ROE of -7.75%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): OptimizeRx's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.4%, the company may face hurdles in generating optimal returns from its assets.

Debt Management: OptimizeRx's debt-to-equity ratio is below the industry average at 0.31, reflecting a lower dependency on debt financing and a more conservative financial approach.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.